PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost
DOI: 10.1055/a-2411-1000
Coagulation and Fibrinolysis

Characteristics of Bleeding Complications in Patients with Severe COVID-19 Requiring Veno-venous Extracorporeal Membrane Oxygenation in Japan

Hayato Taniguchi 
1   Department of Emergency Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
,
Takeru Abe
1   Department of Emergency Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
,
Ichiro Takeuchi
1   Department of Emergency Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
,
Shinichiro Ohshimo
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
3   Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
,
Nobuaki Shime
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
3   Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
,
Shigeki Kushimoto
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
4   Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
,
Satoru Hashimoto
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
5   Non-Profit Organization ICU Collaboration Network (ICON), Tokyo, Japan
,
Shinhiro Takeda
2   Non-profit Organization Japan ECMO Network, Tokyo, Japan
6   Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan
,
on behalf of the Japan ECMO Network › Institutsangaben Funding This research was funded by the Japan Agency for Medical Research and Development (grant number: JP22fk0108654).
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints


Abstract

Background Complications during veno-venous extracorporeal membrane oxygenation (VV-ECMO) are associated with in-hospital mortality. Asian patients on extracorporeal membrane oxygenation (ECMO) have higher risks of bleeding and in-hospital mortality than Caucasian patients. This study aimed to characterize and identify bleeding complications and their associated factors related to in-hospital mortality in patients with severe coronavirus disease 2019 (COVID-19) requiring VV-ECMO in Japan.

Methods In this retrospective observational analysis, the prospective nationwide multicenter registry was used to track real-time information from intensive care units throughout Japan during the COVID-19 pandemic. VV-ECMO patients' registry data between February 1, 2020 and October 31, 2022 were used.

Results This study included 441 patients; 178 (40%) had bleeding complications in the following sites: 20% at the cannulation site, 16% in the gastrointestinal tract, 16% in the ear–nose–throat, 13% at the tracheostomy site, 9% intrathoracic, 6% intracranial, and 5% in the iliopsoas. Anticoagulation was discontinued in >50% of patients with intracranial, iliopsoas, and gastrointestinal tract bleeding. ECMO was discontinued in one-third of patients with intracranial, intramuscular, and iliopsoas hemorrhages. Multivariable logistic regression analysis revealed that only gastrointestinal tract bleeding was associated with in-hospital mortality (odds ratio: 2.49; 95% confidence interval: 1.11–5.60; p = 0.03).

Conclusion Incidence of bleeding complications was 40% in the Japanese population. Gastrointestinal tract bleeding emerged as a significant predictor of adverse outcomes, necessitating further research into preventive strategies and optimized care protocols. These findings can guide the management of VV-ECMO patients with COVID-19.

Keywords

bleeding - coronavirus disease 2019 - gastrointestinal tract - respiratory distress syndrome - mortality

Ethical Approval Statement

This study was approved by the Institutional Review Board of Yokohama City University (approval number: B200700034), and the need for informed consent was waived owing to its retrospective nature. Instead, an opt-out statement was posted on the Web site. The study was conducted according to the principles of the Declaration of Helsinki.


Supplementary Material



Publikationsverlauf

Eingereicht: 18. Juni 2024

Angenommen: 02. September 2024

Accepted Manuscript online:
06. September 2024

Artikel online veröffentlicht:
27. September 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Peek GJ, Mugford M, Tiruvoipati R. et al; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374 (9698) 1351-1363
    CrossrefPubMedSuche in Google Scholar
  • 2 Combes A, Hajage D, Capellier G. et al; EOLIA Trial Group, REVA, and ECMONet. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018; 378 (21) 1965-1975
    CrossrefPubMedSuche in Google Scholar
  • 3 Ramanathan K, Shekar K, Ling RR. et al. Correction to: extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care 2021; 25 (01) 375
    CrossrefPubMedSuche in Google Scholar
  • 4 Urner M, Barnett AG, Bassi GL. et al; COVID-19 Critical Care Consortium Investigators. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ 2022; 377: e068723
    CrossrefPubMedSuche in Google Scholar
  • 5 Ohshimo S, Liu K, Ogura T. et al; Japan ECMO Network. Trends in survival during the pandemic in patients with critical COVID-19 receiving mechanical ventilation with or without ECMO: analysis of the Japanese national registry data. Crit Care 2022; 26 (01) 354
    CrossrefPubMedSuche in Google Scholar
  • 6 Nunez JI, Gosling AF, O'Gara B. et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis. Intensive Care Med 2022; 48 (02) 213-224
    CrossrefPubMedSuche in Google Scholar
  • 7 Willers A, Swol J, Buscher H. et al. Longitudinal trends in bleeding complications on extracorporeal life support over the past two decades-extracorporeal life support organization registry analysis. Crit Care Med 2022; 50 (06) e569-e580
    CrossrefPubMedSuche in Google Scholar
  • 8 Fanning JP, Weaver N, Fanning RB. et al; COVID-19 Critical Care Consortium. Hemorrhage, disseminated intravascular coagulopathy, and thrombosis complications among critically ill patients with COVID-19: an international COVID-19 critical care consortium study. Crit Care Med 2023; 51 (05) 619-631
    CrossrefPubMedSuche in Google Scholar
  • 9 Martucci G, Giani M, Schmidt M. et al; International ECMO Network (ECMONet). Anticoagulation and bleeding during veno-venous extracorporeal membrane oxygenation: insights from the PROTECMO study. Am J Respir Crit Care Med 2024; 209 (04) 417-426
    CrossrefPubMedSuche in Google Scholar
  • 10 Willers A, Swol J, van Kuijk SMJ. et al. HEROES V-V-HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support-Development and internal validation of multivariable prediction model in adult patients. Artif Organs 2022; 46 (05) 932-952
    CrossrefPubMedSuche in Google Scholar
  • 11 Schmidbauer ML, Ferse C, Salih F. et al; On Behalf Of The Ignite Study Group. COVID-19 and intracranial hemorrhage: a multicenter case series, systematic review and pooled analysis. J Clin Med 2022; 11 (03) 605
    CrossrefPubMedSuche in Google Scholar
  • 12 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Richardson S, Verma A, Sanaiha Y. et al. Racial disparities in outcomes for extracorporeal membrane oxygenation in the United States. Am J Surg 2023; 225 (01) 113-117
    CrossrefPubMedSuche in Google Scholar
  • 14 Yusuff H, Zochios V, Brodie D. Thrombosis and coagulopathy in COVID-19 patients rceiving ECMO: a narrative review of current literature. J Cardiothorac Vasc Anesth 2022; 36 (8, Pt B): 3312-3317
    CrossrefPubMedSuche in Google Scholar
  • 15 Mansour A, Flecher E, Schmidt M. et al; ECMOSARS Investigators. Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study. Intensive Care Med 2022; 48 (08) 1039-1052
    CrossrefPubMedSuche in Google Scholar
  • 16 Shaefi S, Brenner SK, Gupta S. et al; STOP-COVID Investigators. Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Med 2021; 47 (02) 208-221
    CrossrefPubMedSuche in Google Scholar
  • 17 Arachchillage DJ, Rajakaruna I, Scott I. et al. Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. Br J Haematol 2022; 196 (03) 566-576
    CrossrefPubMedSuche in Google Scholar
  • 18 Li C, Cai T, Xie H. et al. Risk factors and outcomes for patients with bleeding complications receiving extracorporeal membrane oxygenation: an analysis of the Chinese Extracorporeal Life Support Registry. Artif Organs 2022; 46 (12) 2432-2441
    CrossrefPubMedSuche in Google Scholar
  • 19 Malas J, Chen Q, Shen T. et al. Outcomes of extremely prolonged (> 50 d) venovenous extracorporeal membrane oxygenation support. Crit Care Med 2023; 51 (07) e140-e144
    CrossrefPubMedSuche in Google Scholar
  • 20 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
    Thieme ConnectPubMedSuche in Google Scholar
  • 21 de Oliveira GLV, Oliveira CNS, Pinzan CF, de Salis LVV, Cardoso CRB. Microbiota modulation of the gut-lung axis in COVID-19. Front Immunol 2021; 12: 635471
    CrossrefPubMedSuche in Google Scholar
  • 22 Nichi-Iko Pharmaceutical Co. L. Pharmaceutical interview form for FUTHAN 10 INJ., FUTHAN 50 INJ. 6th ed. [Internet]. 2019 . Accessed August 10, 2024 at: https://www.nichiiko.co.jp/medicine/file/31050/interview
    PubMedSuche in Google Scholar
  • 23 Hernández-Mitre MP, Tong SYC, Denholm JT. et al. Nafamostat mesylate for treatment of COVID-19 in hospitalised patients: a structured, narrative review. Clin Pharmacokinet 2022; 61 (10) 1331-1343
    CrossrefPubMedSuche in Google Scholar
  • 24 Minakata D, Fujiwara SI, Ikeda T. et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol 2019; 109 (02) 141-146
    CrossrefPubMedSuche in Google Scholar
  • 25 Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. COVID-UTH Study Group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care 2020; 24 (01) 392
    CrossrefPubMedSuche in Google Scholar
  • 26 Yoshioka T, Daizumoto K, Tada K. et al. Retroperitoneal hemorrhage in a patient with coronavirus disease 2019 (COVID-19): a case report. J Med Invest 2022; 69 (1.2): 148-151
    CrossrefPubMedSuche in Google Scholar
  • 27 Doi S, Akashi YJ, Takita M. et al. Preventing thrombosis in a COVID-19 patient by combined therapy with nafamostat and heparin during extracorporeal membrane oxygenation. Acute Med Surg 2020; 7 (01) e585
    CrossrefPubMedSuche in Google Scholar
  • 28 Hunsicker O, Beck L, Krannich A. et al. Timing, outcome, and risk factors of intracranial hemorrhage in acute respiratory distress syndrome patients during venovenous extracorporeal membrane oxygenation. Crit Care Med 2021; 49 (02) e120-e129
    CrossrefPubMedSuche in Google Scholar
  • 29 Fletcher-Sandersjöö A, Thelin EP, Bartek Jr J. et al. Incidence, outcome, and predictors of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation: a systematic and narrative review. Front Neurol 2018; 9: 548
    CrossrefPubMedSuche in Google Scholar
  • 30 Arachchillage DRJ, Passariello M, Laffan M. et al. Intracranial hemorrhage and early mortality in patients receiving extracorporeal membrane oxygenation for severe respiratory failure. Semin Thromb Hemost 2018; 44 (03) 276-286
    Thieme ConnectPubMedSuche in Google Scholar
  • 31 Fletcher-Sandersjöö A, Thelin EP, Bartek Jr J, Elmi-Terander A, Broman M, Bellander BM. Management of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation (ECMO): an observational cohort study. PLoS One 2017; 12 (12) e0190365
    CrossrefPubMedSuche in Google Scholar
  • 32 Taniguchi H, Ikeda T, Takeuchi I, Ichiba S. Iliopsoas hematoma in patients undergoing venovenous ECMO. Am J Crit Care 2021; 30 (01) 55-63
    CrossrefPubMedSuche in Google Scholar
  • 33 Taniguchi H, Rätsep I, Heinsar S. et al. Iliopsoas haematoma during extracorporeal membrane oxygenation: a registry report from the COVID-19 critical care consortium across 30 countries. Perfusion 2024; 39 (05) 891-895
    CrossrefPubMedSuche in Google Scholar